Yamaguchi, O., Kaira, K., Hashimoto, K., Mouri, A., Miura, Y., Shiono, A., . . . Kagamu, H. (2019). Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab. Thorac Cancer.
Style de citation ChicagoYamaguchi, Ou, et al. "Radiotherapy Is an Independent Prognostic Marker of Favorable Prognosis in Non‐small Cell Lung Cancer Patients After Treatment With the Immune Checkpoint Inhibitor, Nivolumab." Thorac Cancer 2019.
Style de citation MLAYamaguchi, Ou, et al. "Radiotherapy Is an Independent Prognostic Marker of Favorable Prognosis in Non‐small Cell Lung Cancer Patients After Treatment With the Immune Checkpoint Inhibitor, Nivolumab." Thorac Cancer 2019.